// App-Quantinova.ai

: Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Charlotte Calvo

Principal Investigators

  • Benoit Brethon

  • Aurelie Cabannes-Hamy

  • Dalila Adjaoud

  • Benedicte Bruno

  • Laurence Blanc

  • Nicolas Boissel

  • Marie-Dominique Tabone

  • Andre Baruchel

Medical Centers

  • Pediatric Hematology and Immunology Department, Robert Debré University Hospital (APHP and Paris Diderot University), Paris, France

  • Pediatric Hematology and Immunology Department, Robert Debre hospital, APHP, Paris, France

  • Dermatology Department, Saint Louis Hospital, Paris, France

  • hemato oncologie pédiatrique, CHU de Grenoble, Grenoble, France

  • Hopital Jeanne de Flandre, Lille, France

  • CHU La Miletrie, Poitiers, France

  • Saint-Louis University Hospital, University Paris Diderot, Paris, France

  • Dermatology Department, Saint Louis Hospital, Paris, France

  • Pediatric Immunology, Hematology and Oncology Department, Trousseau Hospital, Paris, France

  • Department of Pediatric Hematology-Immunology, Robert Debre Hospital, Paris, France

  • EA, Leukemia Translational Lab, IUH, University Paris Diderot, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved